JP2013539030A5 - - Google Patents

Download PDF

Info

Publication number
JP2013539030A5
JP2013539030A5 JP2013530205A JP2013530205A JP2013539030A5 JP 2013539030 A5 JP2013539030 A5 JP 2013539030A5 JP 2013530205 A JP2013530205 A JP 2013530205A JP 2013530205 A JP2013530205 A JP 2013530205A JP 2013539030 A5 JP2013539030 A5 JP 2013539030A5
Authority
JP
Japan
Prior art keywords
value
risk
renal
threshold
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539030A (ja
JP5998143B2 (ja
Filing date
Publication date
Priority claimed from US13/235,005 external-priority patent/US10557856B2/en
Application filed filed Critical
Publication of JP2013539030A publication Critical patent/JP2013539030A/ja
Publication of JP2013539030A5 publication Critical patent/JP2013539030A5/ja
Application granted granted Critical
Publication of JP5998143B2 publication Critical patent/JP5998143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530205A 2010-09-24 2011-09-19 腎障害のバイオマーカー Active JP5998143B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38623010P 2010-09-24 2010-09-24
US61/386,230 2010-09-24
US13/235,005 US10557856B2 (en) 2010-09-24 2011-09-16 Biomarkers of renal injury
US13/235,005 2011-09-16
PCT/US2011/052082 WO2012040073A2 (en) 2010-09-24 2011-09-19 Biomarkers of renal injury

Publications (3)

Publication Number Publication Date
JP2013539030A JP2013539030A (ja) 2013-10-17
JP2013539030A5 true JP2013539030A5 (cg-RX-API-DMAC10.html) 2014-11-06
JP5998143B2 JP5998143B2 (ja) 2016-09-28

Family

ID=45871234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530205A Active JP5998143B2 (ja) 2010-09-24 2011-09-19 腎障害のバイオマーカー

Country Status (12)

Country Link
US (3) US10557856B2 (cg-RX-API-DMAC10.html)
EP (1) EP2619577B1 (cg-RX-API-DMAC10.html)
JP (1) JP5998143B2 (cg-RX-API-DMAC10.html)
KR (1) KR101981745B1 (cg-RX-API-DMAC10.html)
CN (1) CN103189745B (cg-RX-API-DMAC10.html)
AU (1) AU2011305786B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013006935B1 (cg-RX-API-DMAC10.html)
CA (1) CA2811658C (cg-RX-API-DMAC10.html)
EA (1) EA030622B1 (cg-RX-API-DMAC10.html)
MX (1) MX365029B (cg-RX-API-DMAC10.html)
NZ (1) NZ608384A (cg-RX-API-DMAC10.html)
WO (1) WO2012040073A2 (cg-RX-API-DMAC10.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107233337A (zh) 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
MX377553B (es) 2009-04-29 2025-03-10 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
BRPI1011883A2 (pt) 2009-06-15 2016-09-13 Amarin Pharma Inc uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
NZ599061A (en) 2009-09-23 2014-05-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130282390A1 (en) * 2012-04-20 2013-10-24 International Business Machines Corporation Combining knowledge and data driven insights for identifying risk factors in healthcare
US20130330829A1 (en) * 2012-06-06 2013-12-12 The Cleveland Clinic Foundation Prediction of acute kidney injury from a post-surgical metabolic blood panel
ES3059226T3 (en) * 2012-10-08 2026-03-19 Vifor Int Ltd Potassium-binding agents for treating hypertension and hyperkalemia
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
ES2836127T3 (es) * 2013-03-15 2021-06-24 Sera Prognostics Inc Biomarcadores y métodos para predecir el parto prematuro
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
GB201317621D0 (en) * 2013-10-04 2013-11-20 Randox Teoranta Kidney disease biomarker
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3254115A4 (en) * 2015-02-05 2018-06-20 University of Florida Research Foundation, Inc. Use of nhe3 as biomarker for radiation biodosimetry
EP3196791A1 (de) * 2017-05-02 2017-07-26 Siemens Healthcare GmbH Verfahren zur unterstützung von medizinischem personal, unterstützungssystem, computerprogramm und datenträger
JP7344127B2 (ja) 2017-05-31 2023-09-13 マース インコーポレーテッド 慢性腎臓病の診断及び治療方法
AU2018313853A1 (en) * 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
CA3089817A1 (en) 2018-01-19 2019-07-25 Mars, Incorporated Biomarkers and classification algorithms for chronic kidney disease in cats
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
US20190317090A1 (en) * 2018-04-12 2019-10-17 Children's Hospital Medical Center Compositions and methods for forecasting response to lupus nephritis (ln)therapy
WO2020006571A1 (en) * 2018-06-29 2020-01-02 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
JP7633147B2 (ja) 2018-07-14 2025-02-19 マース インコーポレーテッド 慢性腎臓病のためのバイオマーカー及びテストモデル
MA50490A (fr) 2018-09-24 2020-09-02 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
CN109754878B (zh) * 2018-11-30 2023-06-20 平安科技(深圳)有限公司 慢性肾病筛查方法、装置、设备及存储介质
CN109738931B (zh) * 2018-12-18 2022-06-17 上海瑞派益尔科技有限公司 一种肾小球滤过率检测设备
US11350887B2 (en) 2019-08-07 2022-06-07 Fresenius Medical Care Holdings, Inc. Systems and methods for detection of potential health issues
CN110596370B (zh) * 2019-09-17 2023-03-24 广州医科大学附属第五医院 一种检测细菌尿路感染的酶联免疫吸附试剂盒及其应用
CA3160676A1 (en) 2019-11-12 2021-05-20 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
CN110923310B (zh) * 2019-12-24 2023-04-18 广州市妇女儿童医疗中心 用于指导肾病综合征cyp3a5表达型患儿使用他克莫司的多态性位点
CN110904219B (zh) * 2019-12-24 2023-04-18 广州市妇女儿童医疗中心 Myh9及ctla4基因多态性位点在指导肾病综合征患儿使用他克莫司中的应用
WO2021247550A1 (en) 2020-06-01 2021-12-09 Mars, Incorporated System and method for chronic kidney disease of a dog
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
RU2761738C1 (ru) * 2021-06-07 2021-12-13 Алина Владимировна Еремеева Способ отбора детей с дебютом острого пиелонефрита для проведения курса противорецидивной терапии пиелонефрита
WO2022261513A1 (en) * 2021-06-10 2022-12-15 Kang Zhang Methods and systems of detecting and predicting chronic kidney disease and type 2 diabetes using deep learning models
WO2024040225A2 (en) * 2022-08-19 2024-02-22 The Johns Hopkins University Diagnosis and treatment of acute kidney injury
TW202515633A (zh) * 2023-06-28 2025-04-16 美商阿比奥梅德公司 心腎綜合症(crs)治療系統和方法
CN117373584B (zh) * 2023-12-08 2024-03-12 北京大学第一医院 一种急性肾损伤的动态预测方法及系统

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6350571B1 (en) 1996-02-01 2002-02-26 Vinata B. Lokeshwar Methods for detection and evaluation of bladder cancer
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
CN101393165A (zh) * 2007-09-20 2009-03-25 复旦大学附属华山医院 一种检测糖尿病肾病血清标本中差异表达的蛋白质谱的方法
CN101960308B (zh) * 2008-02-29 2014-07-09 国立大学法人名古屋大学 急性肾损伤及预后推测用生物标记物以及其用途
US20090239242A1 (en) 2008-03-18 2009-09-24 Biotrin Intellectual Properties Limited Method for the early identification and prediction of kidney injury
JP2012501456A (ja) * 2008-08-28 2012-01-19 アスチュート メディカル,インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8501489B2 (en) 2008-09-26 2013-08-06 University of Pittsburgh—of the Commonwealth System of Higher Education Urinary biomarkers to predict long-term dialysis
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2364370B1 (en) * 2008-11-22 2014-09-03 Astute Medical, Inc. Methods for prognosis of acute renal failure
US20120315649A1 (en) * 2009-08-28 2012-12-13 Astute Medical ,Inc. a corporation Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX342967B (es) * 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.

Similar Documents

Publication Publication Date Title
JP2012517594A5 (cg-RX-API-DMAC10.html)
Kusaka et al. Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death
JP2013501920A5 (cg-RX-API-DMAC10.html)
JP2012517592A5 (cg-RX-API-DMAC10.html)
JP2013519095A5 (cg-RX-API-DMAC10.html)
JP2012517593A5 (cg-RX-API-DMAC10.html)
Jefferies et al. Early detection of acute kidney injury after pediatric cardiac surgery
JP2011520098A5 (cg-RX-API-DMAC10.html)
JP2014529073A5 (cg-RX-API-DMAC10.html)
HRP20160733T1 (hr) Postupci i pripravci za postavljanje dijagnoze i prognoze ozljede bubrega i bubrežne insuficijencije
JP2013503344A5 (cg-RX-API-DMAC10.html)
JP2013539861A5 (cg-RX-API-DMAC10.html)
JP2014521088A5 (cg-RX-API-DMAC10.html)
JP2015504519A5 (cg-RX-API-DMAC10.html)
JP2015508181A5 (cg-RX-API-DMAC10.html)
JP2017534874A5 (cg-RX-API-DMAC10.html)
Delcroix et al. NGAL usefulness in the intensive care unit three hours after cardiac surgery
TWI735470B (zh) 糖尿病性腎病之判定方法、及於此種判定方法中生物標記之用途
JP6062439B2 (ja) 早期腎障害の評価マーカーとその測定方法
JP2015513673A5 (cg-RX-API-DMAC10.html)
JP2013541005A5 (cg-RX-API-DMAC10.html)
RU2812203C1 (ru) Способ ранней диагностики острого повреждения почек-ОПП у пациентов с острой декомпенсацией сердечной недостаточности и хронической болезнью почек
Lelli et al. Role of PDW and MPV in stratification of heart failure severity in older adults
Abdelhamid Association between neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios with chronic allograft nephropathy
Azmy Kamal El Sayed et al. Platelet Indices as Predictive Biomarkers of Diabetic Nephropathy In Type 2 Diabetes Mellitus